Tysabri for the Treatment of Multiple Sclerosis

Biotechnology company Biogen Idec has announced the introduction of TYSABRI (natalizumab) the first humanized, monoclonal antibody for the treatment of relapsing remitting MS in India. TYSABRI inhibits adhesion molecules on the surface of immune cells. Research suggests it works by preventing immune cells from migrating from the bloodstream into the brain where they can cause inflammation and potentially damage nerve fibers and their insulation. MS is a chronic, progressive, and unpredictable inflammatory disease of the central nervous system (CNS).  It primarily affects people between 20 – 40 years of age, and it is seen more frequently in women than men. Typically, when a patient has an MS attack, or relapse, the protective insulation, or myelin sheath, surrounding nerves is damaged.  This damage to the protective insulation causes problems in transmitting nerve impulses, resulting in many of the symptoms seen in MS, including loss of vision, mobility impairment, urinary incontinence, and problems with cognition.  The cause of MS is not yet fully understood and the disease affects each patient differently.   


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video